Gufic Biosciences receives TGA Australia and ANVISA Brazil approval for Parecoxib 40mg injection
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Subscribe To Our Newsletter & Stay Updated